The ranks of our senior leadership are filled with highly knowledgeable, talented individuals. Each has many years of relevant experience and track records of success.

Scott Tarriff

President and Chief Executive Officer, Director

Mr. Tarriff is the founder, president, and chief executive officer of Eagle Pharmaceuticals. Prior to joining Eagle, Mr. Tariff held various executive positions at Par Pharmaceutical Companies, Inc. and Bristol-Meyers Squibb, both publicly traded companies. At Par, he served as president and chief executive officer from September 2003 to September 2006, and was also a member of the board of directors from 2002 to September 2006.

Before that, Mr. Tarriff was a senior director of marketing at Bristol-Meyers Squibb. He also previously served on the board of directors of Clinical Data, Inc., a publicly traded pharmaceutical company, from September 2009 to April 2011 when Clinical Data was acquired by Forest Laboratories, Inc.

He has a BS in marketing from Pennsylvania State University and an MBA from Rider College.

David E. Riggs

Chief Financial Officer

Mr. Riggs is the chief financial officer at Eagle Pharmaceuticals. Prior to joining Eagle Pharmaceuticals, Mr. Riggs served as a healthcare consultant to biotechnology and pharmaceutical companies. Before being a consultant, Mr. Riggs was chief financial officer of Ferring Pharmaceuticals, Inc., a research-driven biopharmaceutical company devoted to isolating, developing, and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology, and osteoarthritis. Going back further, Mr. Riggs held various positions at eXegenics Inc. (now OPCO Health Inc.), eventually becoming chief executive officer. In the past he was also the senior vice president and CFO of Axys Pharmaceuticals, Inc. (acquired by Celera Genomics Inc.), a biopharmaceutical company focused on discovery, design, and development of therapeutic small molecules for large worldwide medical markets.

Earlier in his career, Mr. Riggs held various positions at Unimed Pharmaceuticals, Inc., a company focused on developing and commercializing products in HIV, oncology, and urology specialty markets. Prior to that, Mr. Riggs had been the treasurer and director of financial planning and analysis for Fujisawa Pharmaceuticals, Inc. (acquired by Astellas Pharma, Inc.).

He has a BS in accounting from the University of Illinois and an MBA from DePaul University.

Steven L. Krill, PhD

Executive Vice President/Chief Scientific Officer

Dr. Krill has served as Eagle Pharmaceuticals’ chief scientific officer since February 2013. Before that, he held the position of vice president of pharmaceutical development from October 2011 to February 2013. Prior to joining Eagle Pharmaceuticals, Dr. Krill served as the vice president of scientific affairs at Teva Parenteral Medicines. A few years prior, at Boehringer Ingelheim, Dr. Krill was vice president, pharmaceutical research and development (December 2005 to March 2009) and director of pharmaceutics and investigational supplies (May 2002 to December 2005). He has also held various management positions at Lipocine Inc., Novartis Pharmaceuticals, and Abbott Laboratories.

Dr. Krill is an author of over 30 publications and inventor of multiple patents in the area of drug delivery.

He holds a BS in pharmacy and an MS in pharmaceutical sciences from the University of Cincinnati and a PhD in Pharmaceutics from the University of Utah.

Adrian Hepner, MD, PhD

Executive Vice President and Chief Medical Officer

Dr. Hepner has over 25 years of experience in US and international clinical research and drug development. Included in his experience is the development and implementation of the clinical and regulatory strategy for a number of products from early stage development through successful New Drug Application (NDA) and EU regulatory filings.

After receiving his MD degree, Dr. Hepner completed visiting research physician experiences in the Department of Psychiatry at Harvard Medical School, the Department of Neurology at the National Institute of Mental Health, and a post-doctoral fellowship in neuropharmacology at the University of Ottawa. Additionally, he spent 17 years in neuropsychiatry private practice and participated in multiple clinical research studies.

Dr. Hepner’s pharmaceutical industry experience includes 15 years of progressively increasing drug development responsibilities. He had a critical leading role in the regulatory and clinical activities for FDA approval of the first product for pseudobulbar affect and successfully completing placebo-controlled studies in other indications. Most recently, Dr. Hepner held the role of vice president of clinical research and medical affairs at BioDelivery Sciences International (BDSI), where he led the regulatory review process for the first buccal film approved for the maintenance treatment of opioid dependence. In addition, he had a critical role in the commercial launch of the product.

Prior to BDSI, Dr. Hepner was senior medical director at UCB BioSciences, Inc., where he was responsible for global development projects in the central nervous system therapeutic area. He was also vice president of clinical research at Avanir Pharmaceuticals and led global clinical research projects in Latin America for Teva Pharmaceuticals.

John LaRocca

Executive Vice President and General Counsel

Mr. LaRocca is an executive vice president and general counsel for Eagle Pharmaceuticals, and serves as the company’s chief compliance officer. He joined the company after a 15-year career with Actavis, serving in various functions within the legal department. Most recently he served as deputy general counsel, Americas. Mr. LaRocca was primarily responsible for managing the legal services supporting the branded and generic pharmaceutical businesses of Actavis in Canada, the United States, and Latin America.

Prior to going in-house, Mr. LaRocca was a practicing attorney in New York City for 11 years, specializing in mergers and acquisitions, securities compliance, and commercial litigation.

Mr. LaRocca has a JD from the Columbia School of Law and a BA from Columbia College.

Sherry Korczynski

Senior Vice President, Sales and Marketing

Ms. Korczynski is the senior vice president of marketing of Eagle Pharmaceuticals. She is an accomplished leader and award-winning marketer with more than 20 years of progressive experience in the pharmaceutical industry. Ms. Korczynski joins Eagle from Mylan Specialty, where she most recently served as Vice President of EpiPen® Marketing, driving multi-year double-digit growth for the brand and garnering multiple awards. In that role, Ms. Korczynski’s responsibilities spanned public relations, advocacy, government relations, and alliances. Prior to Mylan, Ms. Korczynski work at Eli Lilly and Company for 15 years in multiple leadership roles within the sales organization, driving rapid growth in branded products. She is a dynamic leader known for surpassing financial objectives, expertly addressing market challenges, and building high-performing teams.

Ms. Korczynski received her MBA from West Virginia University and her BS in Marketing from Penn State University.

Peter Grebow, PhD

Executive Vice President, Research and Development

Dr. Grebow is the executive vice president of research and development. For 10 years prior to working at Eagle Pharmaceuticals, Dr. Grebow held several senior management positions at Cephalon Inc., a biopharmaceutical company that was acquired and became a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. in 2011. He held positions as executive vice president, Cephalon Ventures; executive vice president, technical operations; senior vice president, worldwide business development; and senior vice president, drug development.

Dr. Grebow has served on the board of directors of Optimer Pharmaceuticals, a publicly traded biopharmaceutical company, since February 2009; the board of directors of Q Therapeutics Holdings, Inc., a publicly traded pharmaceutical company, since December 2011; and, the board of directors of GenSpera, Inc., a publicly traded pharmaceutical company, since May 2012.

He has an AB degree in chemistry from Cornell University, an MS in chemistry from Rutgers University and a PhD in physical biochemistry from the University of California, Santa Barbara.

Michael Moran

Vice President, Sales

Mr. Moran is the vice president of sales at Eagle Pharmaceuticals. He is an industry veteran with more than 19 years of experience in pharmaceutical sales. Prior to joining Eagle, he spent eight years in various leadership roles at GlaxoSmithKline, including most recently the role of Field Vice President, in which he oversaw more than 100 sales representatives and increased key customer output by 45% in the diabetes injectable market. His additional accomplishments at GlaxoSmithKline include successfully coordinating several product launches across a global footprint and negotiating the acquisition and co-promotion of additional products. He has received numerous awards in recognition of his outstanding project leadership and sales achievements.

Mr. Moran earned a BS in Business Management from the State University of New York at Empire and completed the Transformational Leadership for Executives program at the University Of Pennsylvania Wharton School Of Business.

 

Meet the Board of Directors.